Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
2.05.2008
Pharmacoeconomics for Biotech CEO's in: "Best Practices in Biotechnology Business Development".
Yali's new book on "Best Practices in Biotechnology Business Development" is now available at LogosPress.
Please email me if you are interested in a pdf of the Pharmacoeconomics chapter.
No comments:
Post a Comment